C4 Therapeutics, Inc.: shareholders and insiders

CCCCNASDAQHealthcare · Biological Products, (No Diagnostic Substances)

Price

$2.65

November 16, 2026Market cap $348M

What Ploutos Investor adds for C4 Therapeutics

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 5 fiscal years, from 2021
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Insiders and their shares

Purchases and sales by officers and directors from Nov 17, 2025 to Nov 13, 2026, from their own Form 4 filings.

16 Form 4s

Bought on the market

–

nobody

Sold on the market

$144.7K

2 people

From Nov 17, 2025 to Nov 17, 2026, the days the chart shows. Change its range and the figures follow.

How the sales were made, as a share of their value

  • Under a set plan85%
  • The rest15%

By year

Insiders' open-market purchases (up) and sales (down), by value, since Nov 17, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.

2026·no buys·sold $144.7K by 2 people

  • 2025: no buys, no sales
  • 2026: no buys, sold $144.7K by 2 people
  • Nov 12, 2026Kendra AdamsChief Financial Officer
    Kind10b5-1
  • Oct 1, 2026Kenneth Carl AndersonDirector
    Kind
  • Oct 1, 2026Donna Roy GroganDirector
    Kind
  • Sep 18, 2026Kendra AdamsChief Financial Officer
    Kind
  • Sep 18, 2026Kendra AdamsChief Financial Officer
    Kind
  • Jul 10, 2026Leonard ReynoChief Medical Officer
    Kind
  • Jul 10, 2026Leonard ReynoChief Medical Officer
    Kind
  • Jul 1, 2026Kenneth Carl AndersonDirector
    Kind
  • Jul 1, 2026Donna Roy GroganDirector
    Kind
  • Jun 1, 2026Kenneth Carl AndersonDirector
    Kind
  • Jan 16, 2026Leonard ReynoChief Medical Officer
    Kind

From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 4, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.

Insiders and their shares

Every buy and sale by CCCC's officers and directors from 2020 up to November 16, 2025, 6 more calendar years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 3 years.

Major holders (over 5%)

Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.

8 Holders over 5%Aug 14, 2026 Latest filing
  • Lynx1 Capital Management LPwith 1 more person
    Share of class9.99%
  • Soleus Private Equity Fund III, L.P.with 8 more persons
    Share of class9.99%
  • RA Capital Management, L.P.with 3 more persons
    Share of class9.90%
  • Sirenia Capital Management LPwith 1 more person
    Share of class9.90%
  • Morgan Stanleywith 2 more persons
    Share of class8.00%
  • BlackRock, Inc.
    Share of class6.90%
  • Squadron Master Fund LPwith 3 more persons
    Share of class6.90%
  • Bain Capital Life Sciences Fund II, L.P.with 2 more persons
    Share of class6.25%
Fell to 5% or less (3)

Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.

  • Point72 Asset Management, L.P.0.20%May 15, 202613G/A
  • Wasatch Advisors LP4.70%Apr 22, 202613G/A
  • OrbiMed Advisors LLC1.00%Feb 17, 202613G/A

From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.

Well-known managers

Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.

Sep 30, 2026 quarter end
  • Citadel Advisors (Griffin)
    In the quarter+67%
  • D.E. Shaw
    In the quarter+64%
  • Renaissance Technologies
    In the quarter+1.6%
  • Point72 (Cohen)
    In the quarter+2.9%
  • Millennium Mgmt (Englander)
    In the quarter-85%

From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).

Short interest

How many of the company's shares have been sold borrowed and not yet bought back, twice a month.

On Oct 15, 2026, 32.5% of its shares outstanding were held short, +5.8% since the report before.

Shares held short
42.72M
32.5%
Since the report before40.40M on Sep 30, 2026
+5.8%
17.0
2.52M
More days to cover thanof 4,578 US-listed companies with enough volume
99%
Report date
Oct 15, 2026
  • Oct 31, 2023: Shares held short 1.91M
  • Nov 15, 2023: Shares held short 1.95M
  • Nov 30, 2023: Shares held short 1.88M
  • Dec 15, 2023: Shares held short 8.10M
  • Dec 29, 2023: Shares held short 4.54M
  • Jan 12, 2024: Shares held short 5.55M
  • Jan 31, 2024: Shares held short 3.35M
  • Feb 15, 2024: Shares held short 3.18M
  • Feb 29, 2024: Shares held short 2.97M
  • Mar 15, 2024: Shares held short 5.29M
  • Mar 28, 2024: Shares held short 9.15M
  • Apr 15, 2024: Shares held short 9.56M
  • Apr 30, 2024: Shares held short 10.14M
  • May 15, 2024: Shares held short 11.34M
  • May 31, 2024: Shares held short 13.26M
  • Jun 14, 2024: Shares held short 14.54M
  • Jun 28, 2024: Shares held short 8.81M
  • Jul 15, 2024: Shares held short 11.63M
  • Jul 31, 2024: Shares held short 10.47M
  • Aug 15, 2024: Shares held short 10.50M
  • Aug 30, 2024: Shares held short 11.63M
  • Sep 13, 2024: Shares held short 11.92M
  • Sep 30, 2024: Shares held short 11.01M
  • Oct 15, 2024: Shares held short 6.65M
  • Oct 31, 2024: Shares held short 5.85M
  • Nov 15, 2024: Shares held short 7.40M
  • Nov 29, 2024: Shares held short 7.99M
  • Dec 13, 2024: Shares held short 8.87M
  • Dec 31, 2024: Shares held short 8.60M
  • Jan 15, 2025: Shares held short 9.28M
  • Jan 31, 2025: Shares held short 7.40M
  • Feb 14, 2025: Shares held short 8.06M
  • Feb 28, 2025: Shares held short 8.55M
  • Mar 14, 2025: Shares held short 8.17M
  • Mar 31, 2025: Shares held short 7.76M
  • Apr 15, 2025: Shares held short 7.73M
  • Apr 30, 2025: Shares held short 6.41M
  • May 15, 2025: Shares held short 6.36M
  • May 30, 2025: Shares held short 6.17M
  • Jun 13, 2025: Shares held short 6.38M
  • Jun 30, 2025: Shares held short 4.96M
  • Jul 15, 2025: Shares held short 4.07M
  • Jul 31, 2025: Shares held short 4.66M
  • Aug 15, 2025: Shares held short 4.15M
  • Aug 29, 2025: Shares held short 3.78M
  • Sep 15, 2025: Shares held short 3.54M
  • Sep 30, 2025: Shares held short 3.52M
  • Oct 15, 2025: Shares held short 3.99M
  • Oct 31, 2025: Shares held short 4.81M
  • Nov 14, 2025: Shares held short 4.85M
  • Nov 28, 2025: Shares held short 5.59M
  • Dec 15, 2025: Shares held short 7.17M
  • Dec 31, 2025: Shares held short 7.28M
  • Jan 15, 2026: Shares held short 7.38M
  • Jan 30, 2026: Shares held short 7.21M
  • Feb 13, 2026: Shares held short 7.12M
  • Feb 27, 2026: Shares held short 8.52M
  • Mar 13, 2026: Shares held short 13.53M
  • Mar 31, 2026: Shares held short 16.16M
  • Apr 15, 2026: Shares held short 21.04M
  • Apr 30, 2026: Shares held short 21.06M
  • May 15, 2026: Shares held short 21.25M
  • May 29, 2026: Shares held short 21.65M
  • Jun 15, 2026: Shares held short 22.25M
  • Jun 30, 2026: Shares held short 25.00M
  • Jul 15, 2026: Shares held short 23.82M
  • Jul 31, 2026: Shares held short 30.43M
  • Aug 14, 2026: Shares held short 34.05M
  • Aug 31, 2026: Shares held short 37.41M
  • Sep 15, 2026: Shares held short 40.19M
  • Sep 30, 2026: Shares held short 40.40M
  • Oct 15, 2026: Shares held short 42.72M

As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.

Short sales in daily trading49.3% of the shares in the last 14 sessions' reported trades were short sales.

In the last 14 sessions, 49.3% of the shares in the reported trades were short sales, against 54.2% in the 14 before.

Last 14 sessionsOct 28, 2026 – Nov 16, 2026
49.3%
The 14 beforeOct 8, 2026 – Oct 27, 2026
54.2%
Change
-4.9 pts
Short sales a dayon average, of 940.2K shares
463.9K
More than atof 3,668 US-listed companies, same days
46%
Median of alleight in ten from 34.7% to 63.8%
50.3%
  • Oct 8, 2026: Short sales 51.7%
  • Oct 9, 2026: Short sales 45.1%
  • Oct 12, 2026: Short sales 47.3%
  • Oct 13, 2026: Short sales 40.2%
  • Oct 14, 2026: Short sales 51.7%
  • Oct 15, 2026: Short sales 44.9%
  • Oct 16, 2026: Short sales 53.7%
  • Oct 19, 2026: Short sales 45.6%
  • Oct 20, 2026: Short sales 53.2%
  • Oct 21, 2026: Short sales 38.4%
  • Oct 22, 2026: Short sales 22.4%
  • Oct 23, 2026: Short sales 87.9%
  • Oct 26, 2026: Short sales 58.3%
  • Oct 27, 2026: Short sales 43%
  • Oct 28, 2026: Short sales 45.7%
  • Oct 29, 2026: Short sales 63%
  • Oct 30, 2026: Short sales 37.3%
  • Nov 2, 2026: Short sales 44.6%
  • Nov 3, 2026: Short sales 25.3%
  • Nov 4, 2026: Short sales 54%
  • Nov 5, 2026: Short sales 57.9%
  • Nov 6, 2026: Short sales 41.7%
  • Nov 9, 2026: Short sales 45.1%
  • Nov 10, 2026: Short sales 61.9%
  • Nov 11, 2026: Short sales 54.8%
  • Nov 12, 2026: Short sales 57.6%
  • Nov 13, 2026: Short sales 43.4%
  • Nov 16, 2026: Short sales 47.6%

This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.

What the insiders hold

The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.

1.26M Insiders' shares1.29% Of the company
  • Leonard ReynoChief Medical Officer
    Directly372.4K
  • Kenneth Carl AndersonDirector
    Directly361.9K
  • Kendra AdamsChief Financial Officer
    Directly337.2K
  • Scott N BoyleChief Business Officer
    Directly107.8K
  • Donna Roy GroganDirector
    Directly79.5K

A lower bound: it counts only the 5 officers and directors with a market trade since Nov 18, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.

The ETFs that hold it

Which of the 269 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.

10 ETFs holding it0.04% The largest weight (IBB)
  • IBBiShares Biotechnology ETF
    Weight in the fund0.04%
  • IWNiShares Russell 2000 Value ETF
    Weight in the fund0.03%
  • IWMiShares Russell 2000 ETF
    Weight in the fund0.01%
  • VTWOVanguard Russell 2000 Index Fund
    Weight in the fund0.01%
  • SCHASchwab U.S. Small-Cap ETF
    Weight in the fund0.01%
  • VXFVanguard Extended Market Index Fund
    Weight in the fund0.01%
  • DFACDimensional U.S. Core Equity 2 ETF
    Weight in the fund0.00%
  • VTIVanguard Total Stock Market Index Fund
    Weight in the fund0.00%
  • SCHBSchwab U.S. Broad Market ETF
    Weight in the fund0.00%
  • DFUSDimensional U.S. Equity Market ETF
    Weight in the fund0.00%

10 of the 269 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.

Institutional investors by quarter

Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.

148 Managers, Q2 2026$548M Value of their positions
  • Q3 2025: Managers 97
  • Q4 2025: Managers 101
  • Q1 2026: Managers 124
  • Q2 2026: Managers 148

Institutional investors by quarter

The fund managers holding CCCC, quarter by quarter, from Q4 2020 to Q2 2025, 19 more quarters

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 12 quarters.

Q2 2026: 148 managers held 118M shares, worth $548M. During the quarter 51 opened a position, 28 closed one, 52 added and 28 trimmed.

The largest holders, Q2 2026

  • Morgan Stanley
    In the quarter-2.3%
  • Ra Capital Management
    In the quarter
  • BlackRock
    In the quarter+285%
  • Lynx1 Capital Management
    In the quarter+4.7%
  • Squadron Capital Management
    In the quarter+220%
  • Bain Capital Life Sciences Investors
    In the quarter
  • JPMorgan Chase
    In the quarter+47%
  • Vanguard Capital Management
    In the quarter+14%
  • Citadel Advisors (Griffin)
    In the quarter+67%
  • Goldman Sachs Group
    In the quarter+48%

From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.

Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.

The full analysis

What do C4 Therapeutics's filings show?

Who buys and sells is one part of C4 Therapeutics's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about CCCC's shareholders

Didn't find what you were looking for?

Ask us
Have CCCC's insiders bought or sold?

From Jun 4, 2026 to Nov 13, 2026 C4 Therapeutics's insiders bought 0 and sold $122.5K of shares on the market. 100% of the sales were under set 10b5-1 plans.

Which well-known managers hold CCCC?

5 of the managers we track held the shares on Sep 30, 2026. The largest position was Citadel Advisors (Griffin)'s, worth $20M.

Is every insider transaction a purchase or a sale?

No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.